Sinovac moves forward with phase 1 pandemic flu trial

By Elaine Rigoli

Tampa, Fla., Aug. 28 - Sinovac Biotech Ltd. said Monday that preliminary results of the phase 1 clinical trial testing a vaccine for pandemic influenza suggests that the vaccine with 10 ug antigen offers the best immunogenicity with the sero positive rate of 78.3%.

The company noted no serious adverse events on the 120 volunteers and said the vaccine is well-tolerated.

The company also added that the government's National Development and Reform Commission has decided to provide financial support to the project.

Sinovac also said it will expand the production capability for pandemic influenza vaccine (H5N1) to 20 million doses per year, which will allow the company to have enough to stockpile the vaccine.

Sinovac, based in Beijing, is a biopharmaceutical company, focused on research, development and commercialization of vaccines designed to combat human infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.